

AugtyroTM (repotrectinib) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy billing (NDC: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Pharmacy Information

Pharmacy NPI: _____ Pharmacy Name: _____

Pharmacy Phone: _____ Pharmacy Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Initial Authorization:**

1. Please indicate diagnosis and information:

 Non-Small Cell Lung Cancer (NSCLC)

A. Is NSCLC locally advanced or metastatic? Yes ___ No ___

B. Is NSCLC ROS1-positive? Yes ___ No ___

C. Will repotrectinib be used as a single agent? Yes ___ No ___

 Solid Tumor

A. Does tumor have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion? Yes ___ No ___

B. Is tumor locally advanced or metastatic or surgical resection is likely to result in severe morbidity?
Yes ___ No ___C. Has tumor progressed following treatment or there is no satisfactory alternative therapy?
Yes ___ No ___

D. Will repotrectinib be used as a single agent? Yes ___ No ___

 Other: _____

Additional information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on repotrectinib? Yes ___ No ___

3. Has member experienced adverse drug reactions related to repotrectinib therapy? Yes ___ No ___

If yes, please specify adverse reactions: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.Fax completed prior authorization request form to
888-601-8461 or submit Electronic Prior Authorization
through CoverMyMeds® or SureScripts.All requested data must be provided. Incomplete forms
or forms without the chart notes will be returned.
Pharmacy Coverage Guidelines are available at
AetnaBetterHealth.com/Oklahoma.**CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.